Xencor, Inc splits its revenue into 3 lines in its filings. The largest line in Q3 of fiscal 2026, the quarter ended Sep 30, 2026 was Royalty at $87.5 million, 75% of the total.
USD in millions. The percent under a figure is the change from the same quarter a year earlier.
| Line |
TTM
Sep 30, 2026
|
Q3 FY2026
Sep 30, 2026
|
Q2 FY2026
Jun 30, 2026
|
Q1 FY2026
Mar 31, 2026
|
Q4 FY2025
Dec 31, 2025
|
Q3 FY2025
Sep 30, 2025
|
Q2 FY2025
Jun 30, 2025
|
Q1 FY2025
Mar 31, 2025
|
Q4 FY2024
Dec 31, 2024
|
|---|---|---|---|---|---|---|---|---|---|
| Revenue |
200
|
117
|
51
|
5
|
28
|
21
|
44
|
33
|
53
|
| Royalty |
156
+103.0%
share 77.6%
|
88
+316.8%
share 75.1%
|
41
+121.5%
share 80.5%
|
4
-75.8%
share 97.8%
|
22
+4387.4%
share 79.5%
|
21
share 100.0%
|
19
share 42.7%
|
18
share 55.7%
|
0
share 0.9%
|
| Milestone |
45
-39.0%
share 22.3%
|
29
share 24.9%
|
10
-60.0%
share 19.5%
|
—
|
6
-82.9%
share 20.5%
|
—
|
25
share 57.3%
|
14
share 44.3%
|
34
share 64.4%
|
| License |
—
|
—
|
—
|
0
share 2.2%
|
—
|
—
|
—
|
—
|
0
share 0.0%
|
How these figures are calculated
Quarterly columns are single-quarter amounts. When a 10-Q reports only a year-to-date total, as cash flow statements do, the quarter is that total minus the previous quarter's year-to-date total. The fourth quarter is the annual report's full year minus the first nine months. A column marked YTD is a year-to-date total, shown when the earlier report needed for the single quarter is missing. USD in millions. Each group is a separate split of total revenue, so the groups are not added together. Share of revenue is that line divided by total revenue. The first column adds the latest year-to-date segment amount to the last fiscal year and subtracts the year-ago year-to-date amount. More on our methodology.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- XNCR (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Pasadena, CA
- SEC filer status
- Accelerated filer
- SEC CIK
- 1326732
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.